After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, OCUL falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Ocular Therapeutix Inc is $2.39B. A total of 2.28 million shares were traded on the day, compared to an average of 2.68M shares.
In the most recent transaction, Saroj Namrata sold 25,865 shares of OCUL for 10.74 per share on Nov 05 ’25. After the transaction, the Chief Business Officer now owns 174,135 company shares. In a previous transaction on Nov 05 ’25, NAMRATA SAROJ bought 25,865 shares at 10.74 per share.
Among the insiders who sold shares, Anderman Todd disposed of 11,132 shares on Oct 08 ’25 at a per-share price of $12.34. This resulted in the Chief Legal Officer holding 87,568 shares of OCUL after the transaction. In another insider transaction, TODD ANDERMAN bought 11,132 shares at $12.34 per share on Oct 08 ’25.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, OCUL has a high of $13.85 and a low of $5.78.
As of this writing, OCUL has an earnings estimate of -$0.35 per share for the current quarter. EPS was calculated based on a consensus of 2.0 estimates, with a high estimate of -$0.34 per share and a lower estimate of -$0.36. The company reported an EPS of -$0.29 in the last quarter
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. OCUL’s latest balance sheet shows that the firm has $164.16M in Cash & Short Term Investments as of fiscal 2021. There were $58.98M in debt and $26.34M in liabilities at the time. Its Book Value Per Share was $1.48, while its Total Shareholder’s Equity was $88.00M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OCUL is Buy with a score of 4.69.
